{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T22:41:19Z","timestamp":1792708879095,"version":"4.5.0"},"reference-count":41,"publisher":"Georg Thieme Verlag KG","issue":"08","funder":[{"name":"Fondazione Policlinico Universitario A. Gemelli IRCCS","award":["Ricerca Corrente-2025"],"award-info":[{"award-number":["Ricerca Corrente-2025"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Thromb Hemost"],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The management of hemophilia A has been transformed by the introduction of extended half-life factor VIII (EHL-FVIII) products. Similarly, the development of extended half-life factor IX (EHL-FIX) products has also impacted the treatment of hemophilia B, improving treatment adherence and reducing bleeding episodes. These bioengineered molecules, created through Fc-fusion, PEGylation, single-chain technologies, or albumin conjugation (particularly for FIX), offer patients reduced infusion frequency while maintaining effective bleed protection. However, the structural modifications of both EHL-FVIII and EHL-FIX pose significant challenges for accurate laboratory monitoring. Traditional one-stage and chromogenic substrate assays often yield discrepant results, varying by reagent, analytical platforms, and product type, complicating clinical decision-making and pharmacokinetic assessments. The thrombin generation assay (TGA) has emerged as a powerful global hemostasis tool that provides a functional readout of a patient's overall coagulation potential. By measuring the enzymatic capacity to generate thrombin over time, TGA offers a more integrated view of hemostatic efficacy than conventional factor activity tests. Although promising, TGA remains limited by lack of standardization, interplatform variability, and absence of validated clinical thresholds. Current data support its use as a complementary tool rather than a replacement for conventional assays. Future prospective studies integrating laboratory and clinical endpoints are required to define its role in precision hemophilia care and to determine whether TGA can better reflect bleeding phenotype and guide individualized therapy. Ultimately, the integration of functional assays into clinical practice will depend on harmonization efforts and demonstration of added clinical value in real-world settings and trials.<\/jats:p>","DOI":"10.1055\/a-2900-6892","type":"journal-article","created":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:13:08Z","timestamp":1783123988000},"page":"937-944","source":"Crossref","is-referenced-by-count":1,"title":["Bridging the Gap in Laboratory Monitoring of Extended Half-Life Factor VIII and IX: Can Thrombin Generation Assays Overcome Assay Discrepancies?"],"prefix":"10.1055","volume":"52","author":[{"given":"Monica","family":"Sacco","sequence":"additional","affiliation":[{"name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Italy","place":["Rome"],"department":["Servizio Malattie Emorragiche e Trombotiche"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raimondo","family":"De Cristofaro","sequence":"additional","affiliation":[{"name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Italy","place":["Rome"],"department":["Servizio Malattie Emorragiche e Trombotiche"]},{"name":"Universit\u00e0 Cattolica del Sacro Cuore, Facolt\u00e0 di Medicina e Chirurgia, Italia","place":["Roma"],"department":["Dipartimento di Medicina e Chirurgia Traslazionale"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8090-9040","authenticated-orcid":false,"given":"Stefano","family":"Lancellotti","sequence":"additional","affiliation":[{"name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Italy","place":["Rome"],"department":["Servizio Malattie Emorragiche e Trombotiche"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2026,7,3]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH guidelines for the management of hemophilia, 3rd edition","volume":"26 suppl 6","author":"A Srivastava","year":"2020","journal-title":"Haemophilia"},{"issue":"02","key":"ref2","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1161\/CIRCULATIONAHA.110.952648","article-title":"Thrombin generation in hemorrhage control and vascular occlusion","volume":"124","author":"K G Mann","year":"2011","journal-title":"Circulation"},{"issue":"06","key":"ref3","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1056\/NEJMoa067659","article-title":"Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia","volume":"357","author":"M J Manco-Johnson","year":"2007","journal-title":"N Engl J Med"},{"issue":"02","key":"ref4","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/jth.13215","article-title":"A critical appraisal of one-stage and chromogenic assays of factor VIII activity","volume":"14","author":"F Peyvandi","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"13","key":"ref5","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1182\/blood-2011-09-382846","article-title":"Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients","volume":"119","author":"J S Powell","year":"2012","journal-title":"Blood"},{"issue":"03","key":"ref6","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/hae.13438","article-title":"Defining extended half-life rFVIII-A critical review of the evidence","volume":"24","author":"J Mahlangu","year":"2018","journal-title":"Haemophilia"},{"issue":"11","key":"ref7","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMoa2002699","article-title":"BIVV001 fusion protein as factor VIII replacement therapy for hemophilia A","volume":"383","author":"B A Konkle","year":"2020","journal-title":"N Engl J Med"},{"issue":"11","key":"ref8","doi-asserted-by":"crossref","first-page":"5696","DOI":"10.1007\/s12325-025-03336-y","article-title":"Comparing real-world outcomes of prophylaxis with extended half-life factor IX (rIX-FP vs. rFIXFc and N9-GP) for haemophilia B: an analysis of medical chart data from Germany","volume":"42","author":"M Olivieri","year":"2025","journal-title":"Adv Ther"},{"issue":"03","key":"ref9","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1055\/s-0037-1598058","article-title":"Factor activity assays for monitoring extended half-life FVIII and factor IX replacement therapies","volume":"43","author":"S Kitchen","year":"2017","journal-title":"Semin Thromb Hemost"},{"issue":"09","key":"ref10","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1111\/jth.15425","article-title":"Considerations on activity assay discrepancies in factor VIII and factor IX products","volume":"19","author":"M V Ovanesov","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"02","key":"ref11","doi-asserted-by":"crossref","first-page":"100070","DOI":"10.1016\/j.rpth.2023.100070","article-title":"Measurement of extended half-life recombinant FVIII molecules: in vitro and ex vivo evidence of relevant assay discrepancies","volume":"7","author":"S Lancellotti","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1055\/a-1282-2251","article-title":"Extended half-life factor VIII\/factor IX products: assay discrepancies and implications for hemophilia management","volume":"40","author":"J Muller","year":"2020","journal-title":"Hamostaseologie"},{"issue":"02","key":"ref13","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1046\/j.1365-2141.2001.02761.x","article-title":"Potency estimation of recombinant factor VIII: effect of assay method and standard","volume":"113","author":"A R Hubbard","year":"2001","journal-title":"Br J Haematol"},{"issue":"06","key":"ref14","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1111\/hae.70115","article-title":"Drug-specific calibration: a solution to reagent variability in extended half-life factor IX activity measurements","volume":"31","author":"F Grand","year":"2025","journal-title":"Haemophilia"},{"issue":"01","key":"ref15","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1159\/000071636","article-title":"Calibrated automated thrombin generation measurement in clotting plasma","volume":"33","author":"H C Hemker","year":"2003","journal-title":"Pathophysiol Haemost Thromb"},{"issue":"04","key":"ref16","doi-asserted-by":"crossref","first-page":"e181","DOI":"10.3324\/haematol.2017.185330","article-title":"Use of thrombin generation assay to personalize treatment of breakthrough bleeds in a patient with hemophilia and inhibitors receiving prophylaxis with emicizumab","volume":"103","author":"Y Dargaud","year":"2018","journal-title":"Haematologica"},{"issue":"02","key":"ref17","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/ijlh.14406","article-title":"Thrombin generation assay to support hematologists in the era of new hemophilia therapies","volume":"47","author":"L Josset","year":"2025","journal-title":"Int J Lab Hematol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/978-1-0716-3175-1_37","article-title":"A review of factor VIII and factor IX assay methods for monitoring extended half-life products in hemophilia A and B","volume":"2663","author":"S Abraham","year":"2023","journal-title":"Methods Mol Biol"},{"issue":"09","key":"ref19","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1182\/blood-2015-03-630897","article-title":"Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A","volume":"126","author":"B A Konkle","year":"2015","journal-title":"Blood"},{"issue":"11","key":"ref20","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1007\/s00277-020-04280-3","article-title":"Direct comparison of two extended half-life PEGylated recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A","volume":"99","author":"A Solms","year":"2020","journal-title":"Ann Hematol"},{"issue":"01","key":"ref21","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1080\/14712598.2018.1416088","article-title":"Lonoctocog alfa (rVIII-SingleChain) for the treatment of haemophilia A","volume":"18","author":"S Raso","year":"2018","journal-title":"Expert Opin Biol Ther"},{"issue":"14","key":"ref22","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1182\/blood-2015-09-669234","article-title":"Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial","volume":"127","author":"E Santagostino","year":"2016","journal-title":"Blood"},{"issue":"04","key":"ref23","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1046\/j.1365-2516.2003.00773.x","article-title":"Standardization of FVIII & FIX assays","volume":"9","author":"T W Barrowcliffe","year":"2003","journal-title":"Haemophilia"},{"issue":"01","key":"ref24","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/hae.13643","article-title":"Analytical variation in factor VIII one-stage and chromogenic assays: experiences from the ECAT external quality assessment programme","volume":"25","author":"I van Moort","year":"2019","journal-title":"Haemophilia"},{"issue":"03","key":"ref25","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/hae.14317","article-title":"Validation of factor VIII activity for monitoring standard and extended half-life products and correlation to thrombin generation assays","volume":"27","author":"C Augustsson","year":"2021","journal-title":"Haemophilia"},{"issue":"01","key":"ref26","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1208\/s12248-011-9309-2","article-title":"PEGylation of a factor VIII-phosphatidylinositol complex: pharmacokinetics and immunogenicity in hemophilia A mice","volume":"14","author":"A Peng","year":"2012","journal-title":"AAPS J"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.biologicals.2020.07.009","article-title":"Summary of the WHO hearing on the development of product-specific reference materials for coagulation factor VIII and factor IX products","volume":"67","author":"M V Ovanesov","year":"2020","journal-title":"Biologicals"},{"issue":"04","key":"ref28","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.transci.2018.07.007","article-title":"Issues complicating precision dosing for factor VIII prophylaxis","volume":"57","author":"L A Valentino","year":"2018","journal-title":"Transfus Apher Sci"},{"issue":"04","key":"ref29","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1111\/jth.15640","article-title":"Thrombin generation for monitoring hemostatic therapy in hemophilia A: a narrative review","volume":"20","author":"M JA Verhagen","year":"2022","journal-title":"J Thromb Haemost"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1033416","DOI":"10.3389\/fcvm.2022.1033416","article-title":"Thrombin generation assays to personalize treatment in bleeding and thrombotic diseases","volume":"9","author":"L LFG Valke","year":"2022","journal-title":"Front Cardiovasc Med"},{"issue":"02","key":"ref31","doi-asserted-by":"crossref","first-page":"100062","DOI":"10.1016\/j.rpth.2023.100062","article-title":"In patients with hemophilia, a decreased thrombin generation profile is associated with a severe bleeding phenotype","volume":"7","author":"M JA Verhagen","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"109045","DOI":"10.1016\/j.thromres.2024.109045","article-title":"Comparative analysis of thrombin generation platforms for patients with coagulation factor deficiencies: a comprehensive assessment","volume":"240","author":"B Haisma","year":"2024","journal-title":"Thromb Res"},{"issue":"01","key":"ref33","doi-asserted-by":"crossref","first-page":"100018","DOI":"10.1016\/j.rpth.2022.100018","article-title":"Thrombin generation and implications for hemophilia therapies: a narrative review","volume":"7","author":"R F Sidonio Jr.","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"issue":"07","key":"ref34","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/j.jtha.2024.03.022","article-title":"Multicenter evaluation of the hemostatic activity of emicizumab in patients with severe hemophilia A","volume":"22","author":"L Josset","year":"2024","journal-title":"J Thromb Haemost"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.blre.2019.03.002","article-title":"Factor VIII: long-established role in haemophilia A and emerging evidence beyond haemostasis","volume":"35","author":"B Samuelson Bannow","year":"2019","journal-title":"Blood Rev"},{"issue":"01","key":"ref36","doi-asserted-by":"crossref","first-page":"25001","DOI":"10.1038\/s41598-024-75747-w","article-title":"Effects of coagulation factors on bone cells and consequences of their absence in haemophilia A patients","volume":"14","author":"G Battafarano","year":"2024","journal-title":"Sci Rep"},{"issue":"08","key":"ref37","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1373\/clinchem.2012.184077","article-title":"Whole-blood thrombin generation monitored with a calibrated automated thrombogram-based assay","volume":"58","author":"M Ninivaggi","year":"2012","journal-title":"Clin Chem"},{"issue":"04","key":"ref38","first-page":"441","article-title":"Thrombin generation assays: what are the current clinical applications?","volume":"52","author":"A Tripodi","year":"2025","journal-title":"Semin Thromb Hemost"},{"issue":"12","key":"ref39","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1111\/jth.15538","article-title":"Clinical use of thrombin generation assays","volume":"19","author":"N B Binder","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"12","key":"ref40","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1111\/jth.15529","article-title":"Thrombin generation assays are versatile tools in blood coagulation analysis: a review of technical features, and applications from research to laboratory routine","volume":"19","author":"F Depasse","year":"2021","journal-title":"J Thromb Haemost"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"173764","DOI":"10.1016\/j.ejphar.2020.173764","article-title":"Pharmacodynamics of eftrenonacog-alfa (rFIX-Fc) in severe hemophilia B patients: a real-life study","volume":"891","author":"S Atsou","year":"2021","journal-title":"Eur J Pharmacol"}],"container-title":["Seminars in Thrombosis and Hemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2900-6892.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T22:33:24Z","timestamp":1792708404000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2900-6892"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":41,"journal-issue":{"issue":"08","published-online":{"date-parts":[[2026,10,22]]},"published-print":{"date-parts":[[2026,11]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2900-6892","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0094-6176","1098-9064"],"issn-type":[{"value":"0094-6176","type":"print"},{"value":"1098-9064","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,3]]}}}